On October 6, 2015, the Innovative Medicines Initiative (IMI) launched its 6^th Call for proposals under IMI 2. This call includes, under the program “Big Data for Better Outcomes programme”, the topic:
Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies.

Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.

Vienna, June 12, 2015 – On behalf of the EUTOS network, Dr Hoffmann will present data of a web-based registry of newly diagnosed CML patients.

Vienna, June 12, 2015 – On behalf of the ELOQUENT-2 investigators, Dr Dimopoulos will present the positive results on Elotuzumab with Lenalidomide from a phase III study in patients with multiple myeloma.

Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.

Vienna, June 12, 2015 –Dr Marneth will discuss the findings of eight new genetic variants in GFI1B that have been discovered in patients with bleeding and platelet disorders and consequences for new therapeutic targets.

Vienna, June 12, 2015 –Dr Mesa will present new data from the phase 3 PERSIST-1 study on improving disease symptoms and quality of life for patients with myelofibrosis.

Vienna, June 12, 2015 – Dr Ehninger will present the results of a phase II randomized study on the safety and efficacy of Sorafenib.

At the Congress of the European Hematology Association (EHA) – attracting 10,000 hematologists from Europe and beyond - the president of EHA, Prof. Christine Chomienne, called upon the European Union to deliver funding for Research into Blood Disorders:

“The hematologists in Europe have done a great work. Now it’s the EU’s turn to deliver.”

By European Alliance for Personalised Medicine (EAPM) Executive Director Denis Horgan (Source: EU Reporter Correspondent | June 5, 2015)

Every year, during the Annual Meeting of the American Society of Hematology, the Ham-Wasserman Lecture is presented. This lectureship was named in honor of two past ASH presidents, the late Dr Thomas Hale Ham and the late Dr Louis R Wasserman. The Ham-Wasserman lecture is traditionally given by an individual from outside the United States who has made a major contribution to our understanding of an area that relates to hematology.

This year Dr Jesus San Miguel was selected for his major contribution in the field of Multiple Myeloma. He will present the Ham-Wasserman Lecture entitled “Multiple Myeloma: A Modern Model for Scientific and Clinical Progress”.

The European Hematology Association (EHA) congratulates 20 promising young researchers recently selected for the Translational Research Training in Hematology 2015 program. EHA and the American Society of Hematology (ASH) are proud to offer them a rigorous yearlong training, mentoring, and networking program in translational hematological research. TRTH faculty is made up of international leaders in hematology who cover biostatistics and biomarkers, genetics and molecular biology, ethics, and phase I clinical study design. The faculty of the program looks forward to working with the selected trainees on their research proposals, and to build collaborative networks for the future. 

 On July 22, the European Commission announced an update of the Work Programme 2014-2015. Hematologists should be aware that in 2015 opportunities are available to them in the Societal Challenge Health, demographic change and wellbeing.

Today, EU Reporter published an article by Ulrich Jäger, past president of the European Hematology Association (EHA) and chair of the European Affairs Committee, highlighting the importance of education and collaboration for the treatment of patients. 

Milan, June 13, 2014 - On Behalf of the RESONATE Investigators, Dr Hillmen will present the results from the Phase III trial in CLL and SLL patients.